Transaction #1844 · Form 4 · 0001193125-25-245262
Corbus Pharmaceuticals Holdings, Inc. · Exercise / conversion · Common Stock, par value $0.0001 per share
Corbus Pharmaceuticals Holdings, Inc. · Transacted October 20, 2025 · Filed October 21, 2025
What does this filing report?
An SEC Form 4 filing for Corbus Pharmaceuticals Holdings, Inc. records an exercise / conversion involving Common Stock, par value $0.0001 per share on October 20, 2025. The reported quantity was 1,060. The filing date is October 21, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0001595097
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 1,060
- Reported price
- 4.8
- Reference value
- 5,088
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 7,251
- Ownership description
- Not reported
- SEC acceptance time
- Oct 21, 2025, 4:54 PM EDT
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Altmeyer Anne ↗
Director
CIK 0001947086
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Filing footnotes & remarks
- F1
- This amount includes 4,800 unvested RSUs that were granted on May 30, 2025 and vest 100% on the one-year anniversary of the date of grant.
- F2
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2024.
- F3
- The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.